My two cents:
1) stock price: basically it's pretty obvious there are no buyers or sellers. We are talking about $150,000 or less in trade volume in a day. Most of the cor stock holders are not willing to sell after the long wait, many are probably on this board. Why buy is the next question? you look at the stock pattern and it's dead, you are not missing an up move, and the RD1 data could hurt you. Based on history you don't give up much upside by waiting. The market cap is way to small for institutional investors at this point, even if they wanted in the volume is pathetic. What institution in this enviroment is going to place a bet on a stock that is about to run out of money, about to release RD1. Oh yah you can tell your boss you bought 50,000 shs and you alone moved the price 15%...your boss says great what will happen when I ask you to sell that tiny little position because it's too small, you don't even pay for you silly time buying the shares... "hmmm I guess boss if you wanted me to sell it tomarrow I would drive the price down 25%." That's right so why don't you focus on something we can actually make some real money, because the jerks over in the morgage departement have already lost everyones yearly bonus!
Wait for the partnership buy in the mid 1's and as others get on board you make money. buy now and the risk reward just does not make sense. Not to mention they could never build a position.
2) R&R: I think Nero is probably right, even more if its simple human behavior rather than planned thinking. Why would RR go out on a limb until RD1 comes out, they were clearly correct the RD2 would not move the stock, once RD1 is out of the way they can evaluate the partnership opportunity. It's this partnership opportunity where their clients will make money not RD1. If I was running RR even, if I was not burned by COR in the past (although I was) why not simply wait for RD1, evaluate partner opportunity, make a reccomendation in front of that partnership and bingo within a month or two of their reccomendation will pay out nicely for their clients. They must have a partner or they will run out of money so it's pretty easy bet they will at least get some deal unless RD1 is a disaster(unlikely).
3)RD1 timeline sounds like he is saying we should have in two weeks which washes with Rogers three weeks (last week), but why not leave a bit of room and say 4 on the outside. If I am running the company I would ask to have data right after labor day if it's good and right before if it's bad.
4) 1500mg: it's pretty unlikely that the 2100 dose did not over shoot the required amount by at least a couple hundred mg, let's say 200 for argument sake. They did get a nice P value at 2100 on just a few patients, it is reasonable to think they would have also had statistical significance at 1900 mg. If they don't screw up RD1, you will see a "drug effect" at 1500mg I have no doubt. Maybe the data is a bit more scattered, but you are going to see some effect, unless you believe 2100 was akin hitting bingo.
all IMO Bioturtle.
Market Data 
Markets 
AI
